Aprea Therapeutics (NASDAQ:APRE) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Aprea Therapeutics (NASDAQ:APRE) posted its earnings results on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.11, FiscalAI reports. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%.

Aprea Therapeutics Stock Performance

Shares of Aprea Therapeutics stock traded up $0.02 during midday trading on Wednesday, hitting $0.68. The company had a trading volume of 18,337 shares, compared to its average volume of 1,020,058. Aprea Therapeutics has a 52-week low of $0.55 and a 52-week high of $1.79. The stock has a market capitalization of $8.40 million, a P/E ratio of -0.44 and a beta of 1.52. The company has a 50 day moving average of $0.71 and a 200 day moving average of $0.77.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.67% of Aprea Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 34.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on APRE. Wedbush reduced their price objective on shares of Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Oppenheimer began coverage on shares of Aprea Therapeutics in a research note on Thursday, May 7th. They set an “outperform” rating and a $5.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $4.07.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.